Purmorphamine
Based on 22 publication(s) in Google Scholar
Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.94%
- No. CAS: 483367-10-8
- Fòrmula: C31H32N6O2
- Peso molecular:520.62
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Purmorphamine
More- Cell. 2025 Jun 26;188(13):3441-3458.e25. [Abstract]
- Mil Med Res. 2020 Nov 1;7(1):52. [Abstract]
- Mil Med Res. 2020 Sep 6;7(1):42. [Abstract]
- Transl Neurodegener. 2024 Oct 29;13(1):53. [Abstract]
- J Exp Clin Cancer Res. 2018 Nov 27;37(1):287. [Abstract]
- Adv Sci (Weinh). 2025 May;12(17):e2411235. [Abstract]
- Pharmacol Res. 2021 Mar:165:105460. [Abstract]
- Burns Trauma. 2019 Sep 23:7:29. [Abstract]
- J Hazard Mater. 2025 Nov 5:499:140149. [Abstract]
- Eur J Pharmacol. 2026 Jan 12:1011:178434. [Abstract]
- Int J Mol Sci. 2024 Apr 9;25(8):4138. [Abstract]
- Glia. 2026 Jun;74(6):e70151. [Abstract]
- Am J Physiol Cell Physiol. 2025 Oct 8. [Abstract]
- Arthritis Res Ther. 2024 Jan 25;26(1):36. [Abstract]
- Med Oncol. 2021 Mar 17;38(4):41. [Abstract]
- J Neurochem. 2026 Feb;170(2):e70363. [Abstract]
- Cancer Med. 2018 Nov;7(11):5704-5715. [Abstract]
- Biochem Biophys Res Commun. 2021 Oct 15:574:1-7. [Abstract]
- Oncol Lett. 2019 Sep;18(3):3081-3091. [Abstract]
- Mol Cell Toxicol. 2025 Oct 23.
- Res Sq. 2025 Apr 24.
- Patent. US20180263995A1.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
WB
-
IF
Actividad biológica
IC50: 1.5 μM (Smoothened)
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| C3H 10T1/2 | EC50 |
0.8 μM
Compound: Purmorph
|
Activity at Smo in mouse C3H10T1/2 cells assessed as induction of cell differentiation into osteoblast incubated for 6 days by alkaline phosphatase assay
Activity at Smo in mouse C3H10T1/2 cells assessed as induction of cell differentiation into osteoblast incubated for 6 days by alkaline phosphatase assay
|
[PMID: 27429255] |
| C3H 10T1/2 | EC50 |
1 μM
Compound: Purmorphamine
|
Induction of osteogenesis in mouse C3H10T1/2 cells assessed as induction of osteoblast specific marker alkaline phosphatase by immunofluorescence method
Induction of osteogenesis in mouse C3H10T1/2 cells assessed as induction of osteoblast specific marker alkaline phosphatase by immunofluorescence method
|
[PMID: 16408003] |
| HEK-293T | IC50 |
1.5 μM
Compound: 3
|
Inhibition of BODIPY-cyclopamine binding to Smo expressed in HEK293T cells after 1 hr by fluorescence microscopy
Inhibition of BODIPY-cyclopamine binding to Smo expressed in HEK293T cells after 1 hr by fluorescence microscopy
|
[PMID: 16408088] |
| Shh Light II | EC50 |
1 μM
Compound: 3
|
Activation of Shh in mouse Shh Light2 cells after 30 hrs by luciferase reporter gene assay
Activation of Shh in mouse Shh Light2 cells after 30 hrs by luciferase reporter gene assay
|
[PMID: 16408088] |
Purmorphamine (10, 20 μM) in combination with sirolimus significantly decreases cell numbers according to the MTT assay. Purmorphamine induces up-regulation of alkaline phosphatase activity and expression of RUNX-2 at day 14. Up-regulation of osteocalcin is detected at the 3 and 5 μM doses of purmorphamine on day 14 post-induction. Matrix mineralization remains unchanged in the presence or absence of purmorphamine[1]. Purmorphamine induces STAT3 phosphorylation in mouse ES cell line ES14 and mesenchymal stem cell line C3H10T1/2[2]. Purmorphamine up-regulates the expressionof markers of the osteoblast phenotype-ALP activity and bone-like nodule formationd-in human bonemarrow mesenchymal cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 483367-10-8
-
Appearance Solid
-
Peso molecular 520.62
-
Fòrmula C31H32N6O2
-
Color White to off-white
-
SMILES
N1(C2=CC=C(NC3=NC(OC4=CC=CC5=C4C=CC=C5)=NC6=C3N=CN6C7CCCCC7)C=C2)CCOCC1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Jun 26;188(13):3441-3458.e25. PMID: 40280132 -
Mil Med Res
Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors. [Abstract]2020 Nov 1;7(1):52. PMID: 33129359 -
Mil Med Res
Efficient and rapid conversion of human astrocytes and ALS mouse model spinal cord astrocytes into motor neuron-like cells by defined small molecules. [Abstract]2020 Sep 6;7(1):42. PMID: 32892745 -
Transl Neurodegener
2024 Oct 29;13(1):53. PMID: 39472972 -
J Exp Clin Cancer Res
Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. [Abstract]2018 Nov 27;37(1):287. PMID: 30482232
Purmorphamine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Nov 27;37(1):287. [Abstract]
MCF-7 cells were incubated with 0.5 μM Purmorphamine (PM) for 24 and 48 h. Hedgehog pathway constituents were examined via western blotting. GAPDH was examined as a loading control. **P <0.01,***P < 0.001.
Purmorphamine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Nov 27;37(1):287. [Abstract]
MCF-7 cells were incubated with 0.5 μM Purmorphamine (PM) for 24 and 48 h. Immunofluorescence staining images of MCF-7 cells showed the expression of USP37 and Hedgehog pathway constituents.
Purmorphamine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Nov 27;37(1):287. [Abstract]
Cell invasion capacity of the NC siRNA group or the USP37 siRNA#2 group treated with 0.5 μM Purmorphamine (PM) (Scale bar: 200 μm).
-
Adv Sci (Weinh)
SIRT3-Mediated Deacetylation of DRP1K711 Prevents Mitochondrial Dysfunction in Parkinson's Disease. [Abstract]2025 May;12(17):e2411235. PMID: 39976201 -
Pharmacol Res
Restoration of early deficiency of axonal guidance signaling by guanxinning injection as a novel therapeutic option for acute ischemic stroke. [Abstract]2021 Mar:165:105460. PMID: 33513357 -
Burns Trauma
Redirecting differentiation of mammary progenitor cells by 3D bioprinted sweat gland microenvironment. [Abstract]2019 Sep 23:7:29. PMID: 31559316 -
J Hazard Mater
Environmental UV filters threaten human neurodevelopment: Disruption of central and peripheral nervous system lineage commitment via WNT signaling dysregulation. [Abstract]2025 Nov 5:499:140149. PMID: 41110322 -
Eur J Pharmacol
Purmorphamine attenuates dexamethasone-induced suppression of neurite outgrowth through sonic hedgehog signaling in Neuro2a cells. [Abstract]2026 Jan 12:1011:178434. PMID: 41349709 -
Int J Mol Sci
Small Molecules Promote the Rapid Generation of Dental Epithelial Cells from Human-Induced Pluripotent Stem Cells. [Abstract]2024 Apr 9;25(8):4138. PMID: 38673725 -
Glia
RXR Gamma Enables Oligodendrocyte Differentiation by Suppressing Sonic Hedgehog Signaling. [Abstract]2026 Jun;74(6):e70151. PMID: 41934103 -
Am J Physiol Cell Physiol
Activation of Smo/Gli1 pathway attenuates cardiac fibrosis by suppressing G1 / S phase transition and cell proliferation in cardiac fibroblasts in mice. [Abstract]2025 Oct 8. PMID: 41060747
Purmorphamine purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2025 Oct 8. [Abstract]
CCK-8 assay of cardiac fibroblasts (CFs) treated with Purmorphamine (Purmo), concentrations ranging from 0.5 μM to15 μM for 48 h (n=12 independent experiments). Statistical analysis: one-way ANOVA with Tukey’s post hoc test. ***P<0.001.
Purmorphamine purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2025 Oct 8. [Abstract]
Cell counting assay of cardiac fibroblasts (CFs) treated with 5 μM Purmorphamine (Purmo) at 0, 24, 48, and 72 h (n=4 independent experiments, scale bar: 50 μm).
Purmorphamine purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2025 Oct 8. [Abstract]
The mice in the myocardial fibrosis intervention group were intraperitoneally injected with Purmorphamine (Purmo) (15 mg/kg body wt/per day) after 7 days of ISO treatment for 14 days. Masson staining evaluated the area of fibrosis at day 21 after drug treatment (n≥5 mice/group, scale bar: 500 μm and 100 μm). Statistical analysis: one-way ANOVA with Tukey’s post hoc test. ***P<0.001, ****P<0.0001.
-
Arthritis Res Ther
Endoplasmic reticulum aminopeptidase 2 regulates CD4+ T cells pyroptosis in rheumatoid arthritis. [Abstract]2024 Jan 25;26(1):36. PMID: 38273310 -
Med Oncol
Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency. [Abstract]2021 Mar 17;38(4):41. PMID: 33730237 -
J Neurochem
Zinc-Mediated Lysosomal Destabilization Links Mitochondrial Damage to Neuronal Death in a Cellular MPP+ Model of Parkinson's Disease. [Abstract]2026 Feb;170(2):e70363. PMID: 41622607 -
Cancer Med
Dihydroartemisinin induces apoptosis and inhibits proliferation, migration, and invasion in epithelial ovarian cancer via inhibition of the hedgehog signaling pathway. [Abstract]2018 Nov;7(11):5704-5715. PMID: 30338663
Purmorphamine purchased from MedChemExpress. Usage Cited in: Cancer Med. 2018 Nov;7(11):5704-5715. [Abstract]
The Hh signaling pathway is involved in DHA induced inhibition of cell proliferation. A and B, CCK8 assay of SKOV3 and SKOV3-IP cells is conducted following treatment with purmorphamine, DHA or a combination of DHA and purmorphamine for 48 h. C and D, SKOV3 and SKOV3‐IP cells are treated with GANT61, DHA, or a combination of DHA and GATN61 for 48 h, while controls are treated with DMSO. CCK8 assay is used to analyze cell viability of SKOV3 and SKOV3-IP cells.
-
Biochem Biophys Res Commun
Disruption of Gprasp2 down-regulates Hedgehog signaling and leads to apoptosis in auditory cells. [Abstract]2021 Oct 15:574:1-7. PMID: 34418635 -
Oncol Lett
2019 Sep;18(3):3081-3091. PMID: 31452785 -
-
-
Solvente y solubilidad
DMSO : 33.33 mg/mL (64.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
To determine non-toxic doses of the small molecules, 5×105 passaged-3 human MSCs are seeded in each well of a six-well culture plate and incubated in expansion medium (as mentioned above) at 37°Cand 5% CO2. Two days later, the medium is exchanged with osteogenic medium (OM) that consisted of α-MEM supplemented with 10% FBS, 10 nM dexamethasone, 50 μg/mL ascorbic acid 2-phosphate, and 10 mM beta-glycerol phosphate. This OM is supplemented with different concentrations of purmorphamine (1, 3, 5, 10, and 20 μM) and sirolimus (0.1, 1, 10, 100, and 200 nM). The cultures are maintained for an additional two days and then assessed for the presence of viable cells with the MTT assay, by the addition of MTT solution (5 mg/mL in PBS) to the medium at a ratio of 1:5. Cells are then incubated at 37°C and 5% CO2. Two hours later, the medium is removed and 500 μL of DMSO is added to the treated cells in order to dissolve the formazone precipitate. The optical absorption rate is read at 570 nm. Cell viability is calculated as percent value relative to the control group which is only treated with OM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (282 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Beloti MM, et al. Purmorphamine enhances osteogenic activity of human osteoblasts derived from bone marrow mesenchymal cells. Cell Biol Int. 2005 Jul;29(7):537-41.. . . . [Content Brief]
[2]. Gu D, et al. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. J Biol Chem. 2012 Nov 2;287(45):38356-66. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9208 mL | 9.6039 mL | 19.2079 mL | 48.0197 mL |
| 5 mM | 0.3842 mL | 1.9208 mL | 3.8416 mL | 9.6039 mL | |
| 10 mM | 0.1921 mL | 0.9604 mL | 1.9208 mL | 4.8020 mL | |
| 15 mM | 0.1281 mL | 0.6403 mL | 1.2805 mL | 3.2013 mL | |
| 20 mM | 0.0960 mL | 0.4802 mL | 0.9604 mL | 2.4010 mL | |
| 25 mM | 0.0768 mL | 0.3842 mL | 0.7683 mL | 1.9208 mL | |
| 30 mM | 0.0640 mL | 0.3201 mL | 0.6403 mL | 1.6007 mL | |
| 40 mM | 0.0480 mL | 0.2401 mL | 0.4802 mL | 1.2005 mL | |
| 50 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.9604 mL | |
| 60 mM | 0.0320 mL | 0.1601 mL | 0.3201 mL | 0.8003 mL |
Purmorphamine Related Classifications
HY-15108 Related Classifications
Powered by Bioz